NCT07687017Recruiting
CRP Apheresis in Infarct-Related Cardiogenic Shock
Selective C-Reactive Protein Apheresis in Cardiogenic Shock Complicating Acute Myocardial Infarction (CRP-SHOCK Trial)
Source: ClinicalTrials.gov · Last updated 27 Oct 2026
Brief summary (registry, in English)
Cardiogenic shock complicating acute myocardial infarction remains associated with high short-term mortality despite guideline-directed therapy. Systemic inflammation, particularly elevated C-reactive protein (CRP), may contribute to ongoing myocardial injury and organ dysfunction. The CRP-SHOCK trial is an investigator-initiated, prospective, randomized, open-label, multicenter pilot study evaluating selective CRP apheresis as an adjunct to standard of care in patients with infarct-related cardiogenic shock. Patients are randomized to receive either standard therapy alone or standard therapy plus selective CRP apheresis using the PentraSorb®-CRP system. The primary objective is to assess the effect of CRP apheresis on the CLIP score at 66 ± 8 hours after randomization. Secondary objectives include clinical outcomes, inflammatory biomarkers, and safety endpoints.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 50 (estimated)
- First submitted
- 31 Mar 2026
- Start date
- 16 Oct 2026
- Primary completion date
- 30 Sept 2027
- Lead sponsor
- Leipzig Heart Science gGmbH
- Diseases
- Coronary artery disease
- NCT number
- NCT07687017
What you commit to
- Study type: Interventional
- Planned participants: 50
- From 16 Oct 2026 to the primary completion date, 30 Sept 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Life expectancy \<12 months prior to cardiogenic shock.
Other illness
- Fever (body temperature \>38°C) or acute infection with fever within the last 14 days.
- Chronic inflammatory disease.
- Known history of severe hepatic failure.
- Cardiogenic shock due to causes other than acute myocardial infarction.
Lab values
- Chronic kidney disease with creatinine clearance \<30 mL/min/1.73 m² prior to hospital admission.
Age
- Age \>80 years.
Other
- Participation in another interventional clinical trial.
- Pregnancy.
- Resuscitation duration \>30 minutes.
- Onset of cardiogenic shock \>12 hours before randomization.
Who the study is looking for
- Cardiogenic shock complicating acute myocardial infarction with planned revascularization by percutaneous coronary intervention (PCI).
- Cardiogenic shock defined as:
- Systolic blood pressure \<90 mmHg for \>30 minutes or requirement of catecholamine infusion to maintain systolic blood pressure ≥90 mmHg, and
- Signs of impaired organ perfusion (at least one of the following): Cold, clammy skin and extremities, Altered mental status, Oliguria with urine output \<30 mL/hour, Arterial lactate \>2 mmol/L
- C-reactive protein (CRP) level ≥7 mg/L at baseline.
- Age ≥18 years.
- Informed consent provided by the participant or, if the participant is unable to consent, inclusion after assessment and documentation of the presumed patient's will by two physicians (one independent), with informed consent obtained as soon as possible.
Age in the registry: 18 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Heart Center Leipzig at University of Leipzig Coordinator of this site? Confirm its status | Leipzig | Germany | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.